Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment

by B2i | Sep 15, 2022 | Press Releases

Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md., Sept. 15, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that it has been awarded patents in the...

Shuttle Pharmaceuticals Announces Closing of Initial Public Offering

by B2i | Sep 6, 2022 | Press Releases

ROCKVILLE, Md., Sept. 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol “SHPH”

by B2i | Aug 31, 2022 | Press Releases

Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effectsROCKVILLE, Md., Aug. 31, 2022 — Shuttle Pharmaceuticals Holdings,...

Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering

by B2i | Aug 30, 2022 | Press Releases

ROCKVILLE, Md., Aug. 30, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...

Shuttle Pharma Awarded a New Patent for Selective Inhibitors for Cancer Treatment

by B2i | Jul 29, 2021 | Press Releases

ROCKVILLE, Md., July 29, 2021 — Shuttle Pharmaceuticals Holdings, Inc (Shuttle Pharma), a Maryland-based developer of new drugs for cancer treatment, was awarded US Patent No.: 11,034,667 B2 for “Selective Histone Deacetylase Inhibitors for the treatment...